Literature DB >> 21614457

[Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry].

Friedrich M Fruhwald1, Hanno Ulmer, Richard Pacher, Gerhard Pölzl, Claudia Dornaus, Manfred Wieser, Christian Ebner, Susanne Reiter, Lalit Kaltenbach, Johann Altenberger.   

Abstract

PURPOSE: Elevated heart rate (70 beats per minute-bpm or more) is a predictor of impaired prognosis in patients with ischemic heart failure. The Austrian Working Group on Heart Failure has established a registry in May 2006 for all patients referred to dedicated heart failure clinics with a planned follow-up after 12 ± 3 months. Here we report an analysis of the prognostic impact of elevated heart rate at referral in a well-defined cohort of heart failure patients.
METHODS: Between May 2006 and October 2009 1904 patients have been documented in the Austrian Heart Failure Registry. One thousand threehundred and sixty three patients (72%) had sinus rhythm at referral. Kaplan-Meier and Cox proportional hazards regression analyses were used to compare overall and cardiovascular mortality between high (70 bpm or more) and low heart-rate groups. Patients who were lost-to-follow-up (n = 166) were censored at the time of last contact.
RESULTS: At baseline in 793 patients (58%) heart rate has been elevated (70 bpm or more) while in 562 patients it has been below 70 bpm, in 8 patients no baseline heart rate has been recorded. Groups were equally balanced regarding age, gender and cardiovascular risk factors with the exception of smokers (more active smokers in the high heart-rate group: 23 vs 14%; p = 0.001) and valvular cause of heart failure (more frequent in the high heart-rate group: 3% vs 1%; p = 0.012). Patients in the high heart-rate group had significantly higher median NT-pro-BNP (1470 pg/ml, IQR 499-4188 pg/ml) compared to patients in the low heart-rate group (784 pg/ml, IQR 314-2162 pg/ml; p < 0.001). NYHA functional classes III and IV have been more frequent in the high heart-rate group than in the low heart-rate group (32% and 22%, respectively; p < 0.001) while reduced left ventricular ejection fraction (39% or less) has been more frequent in the high heart-rate group than in the low heart-rate group (71% and 61%, respectively; p < 0.001). In the high heart-rate group treatment with beta-blockers has been less frequent than in the low heart rate group (76% and 86%, respectively; p < 0.01) while dosage of beta-blocker therapy has been comparable in both groups. Of the 75 patients who died within 3.5 years 38 deaths had a cardiovascular cause. Cox proportional hazards analysis revealed that high NYHA functional class (III and IV) and elevated heart rate (70 bpm or more) were the best predictors of overall mortality while cardiovascular mortality could best be predicted by NYHA functional classes III and IV.
CONCLUSION: Higher NYHA-functional classes and elevated heart rate are predictors of adverse outcome in chronic heart failure patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21614457     DOI: 10.1007/s00508-011-1591-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  17 in total

1.  EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot).

Authors:  Aldo P Maggioni; Ulf Dahlström; Gerasimos Filippatos; Ovidiu Chioncel; Marisa Crespo Leiro; Jaroslaw Drozdz; Friedrich Fruhwald; Lars Gullestad; Damien Logeart; Marco Metra; John Parissis; Hans Persson; Piotr Ponikowski; Mathias Rauchhaus; Adriaan Voors; Olav Wendelboe Nielsen; Faiez Zannad; Luigi Tavazzi
Journal:  Eur J Heart Fail       Date:  2010-08-29       Impact factor: 15.534

Review 2.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur J Heart Fail       Date:  2008-09-16       Impact factor: 15.534

3.  More 'malignant' than cancer? Five-year survival following a first admission for heart failure.

Authors:  S Stewart; K MacIntyre; D J Hole; S Capewell; J J McMurray
Journal:  Eur J Heart Fail       Date:  2001-06       Impact factor: 15.534

4.  Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine.

Authors:  F Zannad; S Briancon; Y Juilliere; P M Mertes; J P Villemot; F Alla; J M Virion
Journal:  J Am Coll Cardiol       Date:  1999-03       Impact factor: 24.094

5.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.

Authors:  Michel Komajda; Pablo Lapuerta; Nancy Hermans; José Ramon Gonzalez-Juanatey; Dirk J van Veldhuisen; Erland Erdmann; Luigi Tavazzi; Philip Poole-Wilson; Claude Le Pen
Journal:  Eur Heart J       Date:  2005-04-12       Impact factor: 29.983

6.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

7.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

8.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.

Authors:  M Komajda; F Follath; K Swedberg; J Cleland; J C Aguilar; A Cohen-Solal; R Dietz; A Gavazzi; W H Van Gilst; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; J Widimsky; N Freemantle; J Eastaugh; J Mason
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

9.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

Authors:  J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

10.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.

Authors:  Kim Fox; Ian Ford; P Gabriel Steg; Michal Tendera; Michele Robertson; Roberto Ferrari
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

View more
  2 in total

1.  Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry.

Authors:  W von Scheidt; C Zugck; M Pauschinger; R Hambrecht; O Bruder; A Hartmann; M Rauchhaus; R Zahn; J Brachmann; U Tebbe; T Neumann; R H Strasser; M Böhm; S Störk; M Hochadel; P Heidemann; J Senges
Journal:  Clin Res Cardiol       Date:  2014-07-23       Impact factor: 5.460

2.  Chronic kidney disease: an independent risk factor of all-cause mortality for elderly Chinese patients with chronic heart failure.

Authors:  Shi-Hui Fu; Bing Zhu; Yu-Xiao Zhang; Shuang-Yan Yi; Yuan Liu; Tie-Hui Xiao; Liang Wang; Yong-Yi Bai; Cai-Yi Lu; Ping Ye; Lei-Ming Luo
Journal:  J Geriatr Cardiol       Date:  2012-12       Impact factor: 3.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.